The Voice of the Board by Araszkiewcz, Aleksandra
1The Voice of the Board
Dear Colleagues,
In recent years, significant progress has been 
made in the treatment of diabetes. This includes the 
introduction of new antihyperglycaemic drugs and 
new insulin molecules into clinical practice, as well as 
a much wider use of modern technologies supporting 
glycaemic monitoring and insulin therapy. In the light 
of these facts, a question should be asked about the 
latest data on the incidence of chronic diabetes com-
plications.
We are pleased that in 2017 the current position 
statements of the American Diabetes Association 
(ADA) on the pathogenesis, prevention and treatment 
standards of neuropathy and diabetic retinopathy were 
published. The concept of neurovascular basis for the 
development of complications was established, and the 
need to search for new, innovative diagnostic tests of 
their early stages was emphasized. In this respect, rese-
arch has been recently conducted on the possibility of 
introducing into clinical practice assessments of sweat 
gland function disorders and nerve fibre density in skin 
biopsy material as indicators of small fibre neuropathy. 
The authors of the ADA guidelines emphasize that the 
basis for the diagnosis of peripheral polyneuropathy is 
still primarily the assessment of subjective symptoms as 
well as sensation of touch, vibration and temperature, 
whereas nerve conduction studies should be performed 
in dubious cases with an atypical course. Clinical eva-
luation is extremely important due to the fact that up 
to 50% of patients with neuropathy are asymptomatic.
Screening for retinopathy should be performed 
at the time of diagnosis of diabetes in patients with 
type 2 diabetes and after 5 years of the disease in type 1 
diabetes. Then, the assessment should be considered 
every two years if the results of two consecutive tests 
are correct. The authors of the position statement 
on diabetic retinopathy emphasize the significant 
progress made in the field of diagnostic methods and 
treatment of ocular complications in patients with 
diabetes. The optical coherence tomography (OCT), as 
a method enabling measurement of retinal thickness 
and non-invasive assessment of macular oedema, as 
well as wide-angle fundus photography has been wi-
dely introduced into clinical practice. This allowed for 
earlier and more precise diagnosis of previously elusive 
diabetic lesions. Additional feature of the OCT, which 
may be used in the near future, is its vascular program 
enabling precise, quantitative evaluation of the retinal 
and choroidal vasculature. Demonstrating changes in 
retinal vessels that precede the disclosure of retino-
pathy in traditional ophthalmoscopy is of great clinical 
significance. It is known that the diagnosis of diabetic 
retinopathy at the stage of benign non-proliferative 
lesions allows the interventions that may reverse the 
pathology. Another significant advance in recent years 
has been the introduction and establishing the role of 
intravitreal injections of anti-VEGF preparations in the 
treatment of macular oedema. Epidemiological data 
have already shown a reduction in the proportion of 
diabetic patients diagnosed with diabetic retinopathy 
in studies published after 2000.
This year, I had the opportunity to participate again 
in the meeting of NEURODIAB [a study group of the 
European Association for the Study of Diabetes (EASD) 
with special responsibility for diabetic neuropathy] 
which took place from 9 to 11 September 2017 in 
Coimbra. I always consider these meetings as an op-
portunity to exchange experiences and present my own 
research results. More importantly, the participants can 
compare research work and clinical experience in the 
field of neuropathy between leading centres in Europe 
and in the world. NEURODIAB meetings have inspired 
me to make an attempt to introduce into Polish clinical 
practice the diagnostic methods already implemented 
in the world. Time will show whether they will be ad-
opted into everyday practice and contribute to the ear-
lier detection of diabetic retinopathy and neuropathy.
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